Tests VX-880 in adults with type 1 diabetes who had a kidney transplant
Tests VX-880 in adults with type 1 diabetes who received a kidney transplant.
Key facts
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Where
- Madison, Philadelphia, and Pittsburgh, United StatesSee the 3 sitesAlso in 2 other countries, 4 sites
- Trial code
- Registry title
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 10 people, planned
- Started
- 31 Mar 2025
- Expected to end
- 17 Sept 2027
- Type of study
- Interventional
- Treatments tested
- Biological/Vaccine
- Record updated
- 23 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who have had a kidney transplant. It tests a treatment called VX-880.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes with at least 5 years of needing insulin, and a kidney transplant.
- Earlier treatment
- Must have been on a stable anti-rejection medicine regimen of tacrolimus plus mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks. Must not have had an islet cell transplant, another organ transplant besides kidney, or cell therapy (except a pancreas graft that failed within the first 4 weeks).
Main reasons for not taking part
- Prior islet cell transplant
- Organ transplant other than kidney
- Prior cell therapy
- More than 1 kidney transplant procedure
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
- Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
- Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Who cannot take part
- Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
- Participants had >1 kidney transplant procedure; Other protocol defined Inclusion/Exclusion criteria may apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
Also in 2 other countries, 4 sites
- UW University Hospital - EndocrinologyMadison, United StatesTaking people
- Perelman Center for Advanced Medicine - EndocrinologyPhiladelphia, United StatesTaking people
- Montefiore Clinical and Translational Research Center - EndocrinologyPittsburgh, United StatesTaking people
About the trial
What the trial wants to find out
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
The group in the trial
- VX-880Treatment being tested
Treatment: Biological/Vaccine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant
- Plain-language title
- Tests VX-880 in adults with type 1 diabetes who had a kidney transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06832410, who can take part
- Record updated
- 23 March 2026